Investigation of Metronidazole Use during Pregnancy and Adverse Birth Outcomes

ABSTRACT To assess whether treatment with metronidazole during pregnancy is associated with preterm birth, low birth weight, or major congenital anomalies, we conducted chart reviews and an analysis of electronic data from a cohort of women delivering at an urban New York State hospital. Of 2,829 singleton/mother pairs, 922 (32.6%) mothers were treated with metronidazole for clinical indications, 348 (12.3%) during the first trimester of pregnancy and 553 (19.5%) in the second or third trimester. There were 333 (11.8%) preterm births, 262 (9.3%) infants of low birth weight, and 52 infants (1.8%) with congenital anomalies. In multivariable analysis, no association was found between metronidazole treatment and preterm birth (odds ratio [OR], 1.02 [95% confidence interval [CI], 0.80 to 1.32]), low birth weight (OR, 1.05 [95% CI, 0.77 to 1.43]), or treatment in the first trimester and congenital anomalies (OR, 0.86 [0.30 to 2.45]). We found no association between metronidazole treatment during the first or later trimesters of pregnancy and preterm birth, low birth weight, or congenital anomalies.

[1]  R. Aubry,et al.  Evaluation of Syracuse Healthy Start’s Program for Abnormal Flora Management to Reduce Preterm Birth Among Pregnant Women , 2011, Maternal and Child Health Journal.

[2]  N. Sewankambo,et al.  Treatment of Trichomonas in pregnancy and adverse outcomes of pregnancy: a subanalysis of a randomized trial in Rakai, Uganda. , 2003, American journal of obstetrics and gynecology.

[3]  David B. Callahan,et al.  Bacterial Vaginosis in Pregnancy:: Diagnosis and Treatment Practices of Physicians in San Diego, California, 1999 , 2003, Sexually transmitted diseases.

[4]  Alexandra Kaider,et al.  Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. , 2003, American journal of obstetrics and gynecology.

[5]  B. Sibai,et al.  Randomized Clinical Trial of Metronidazole Plus Erythromycin to Prevent Spontaneous Preterm Delivery in Fetal Fibronectin–Positive Women , 2003, Obstetrics and gynecology.

[6]  D. Grové,et al.  Preterm labour--is bacterial vaginosis involved? , 2002, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[7]  Brett A. Collins,et al.  Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. , 2001, The New England journal of medicine.

[8]  A. Ornoy,et al.  Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. , 2001, Teratology.

[9]  J. Carey,et al.  Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis , 2001 .

[10]  Ichael,et al.  METRONIDAZOLE TO PREVENT PRETERM DELIVERY IN PREGNANT WOMEN WITH ASYMPTOMATIC BACTERIAL VAGINOSIS , 2000 .

[11]  H. Sørensen,et al.  Safety of metronidazole during pregnancy: a cohort study of risk of congenital abnormalities, preterm delivery and low birth weight in 124 women. , 1999, The Journal of antimicrobial chemotherapy.

[12]  A. Czeizel,et al.  A population based case‐control teratologic study of oral metronidazole treatment during pregnancy , 1998, British journal of obstetrics and gynaecology.

[13]  R. Gibbs,et al.  Assessment of office-based care of sexually transmitted diseases and vaginitis and antibiotic decision-making by obstetrician-gynecologists. , 1998, Infectious diseases in obstetrics and gynecology.

[14]  A. Carvajal,et al.  Is metronidazole teratogenic? A meta-analysis. , 2003, British journal of clinical pharmacology.

[15]  M. Krohn,et al.  Trichomonas vaginalis Associated With Low Birth Weight and Preterm Delivery , 1997, Sexually transmitted diseases.

[16]  J. Hauth,et al.  Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis , 1995, The New England journal of medicine.

[17]  T. Einarson,et al.  Safety of metronidazole in pregnancy: a meta-analysis. , 1995, American journal of obstetrics and gynecology.

[18]  L. Brubaker,et al.  Pharmacokinetics of Intravaginal Metronidazole Gel , 1994, Journal of clinical pharmacology.

[19]  R. Sram,et al.  Genotoxicity and carcinogenicity of metronidazole. , 1994, Mutation research.

[20]  W. Ray,et al.  Prenatal Use of Metronidazole and Birth Defects: No Association , 1993, Obstetrics and gynecology.

[21]  Henry Nider,et al.  Report of the Committee on Infectious Diseases , 1989 .

[22]  C. Baum,et al.  Pregnancy outcomes after first-trimester vaginitis drug therapy. , 1987, Obstetrics and gynecology.

[23]  F. Greenberg,et al.  Possible metronidazole teratogenicity and clefting. , 1985, American journal of medical genetics.

[24]  Giuseppe Attardi,et al.  Midline facial defect as a teratogenic effect of metronidazole. , 1982 .

[25]  J. Cantú,et al.  Midline facial defect as a teratogenic effect of metronidazole. , 1982, Birth defects original article series.

[26]  W. O'Fallon,et al.  Lack of evidence for cancer due to use of metronidazole. , 1979, The New England journal of medicine.

[27]  P. Shubik,et al.  Experimental induction of hepatomas, mammary tumors, and other tumors with metronidazole in noninbred Sas:MRC(WI)BR rats. , 1979, Journal of the National Cancer Institute.